Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEM 307

Next Previous
X
Search
Drug Profile

GEM 307

Alternative Names: GEM-307

Latest Information Update: 28 Sep 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gemini Therapeutics
  • Developer Disc Medicine
  • Class Monoclonal antibodies; Urologics
  • Mechanism of Action Complement factor H stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Kidney disorders

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for preclinical development in Kidney-disorders in USA
  • 29 Dec 2022 Gemini Therapeutics has merged with Disc Medicine to form Disc Medicine
  • 01 Mar 2022 Gemini Therapeutics and Sanquin Blood Supply Foundation has pending patent applications for patent family directed to the specific GEM 307 in the US, Argentina, Australia, Brazil, Canada, China, Europe, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, South Africa and Taiwan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top